drugset
Drugs / Trifluridine/Tipiracil
last change Jun 2026 re-read 9 days ago

Trifluridine/Tipiracil

also known as TAS-102
Developed for
colorectal cancer
Investigated by
Tianjin Medical University Cancer Institute and Hospital

Trials 1

today NCT07491159 · Ph 1/2
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07491159 Jul 2023 → Jun 2026 overdue colorectal cancer Tianjin Medical University Cancer Institute and Hospital Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2023-04-18 Taiho Oncology, Inc. Regulatory U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology’s Supplemental New Drug Application for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer taihooncology.com ↗
2019-10-14 Taiho Oncology, Inc. Results Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology taihooncology.com ↗
The safety profile of LONSURF was consistent with studies of the drug in metastatic colorectal cancer (mCRC), and no new safety concerns were reported.
2019-02-25 Taiho Oncology, Inc. Regulatory FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma taihooncology.com ↗
2019-01-17 Taiho Oncology, Inc. Results Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗
The results confirmed that LONSURF prolonged survival versus placebo regardless of prior gastrectomy.
2018-10-25 Taiho Oncology, Inc. Regulatory FDA Accepts Supplemental New Drug Application for LONSURF® (trifluridine/tipiracil) for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma; Grants Priority Review taihooncology.com ↗
2018-10-21 Taiho Oncology, Inc. Results Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology taihooncology.com ↗
The trial met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS), as well as continued to demonstrate LONSURF’s predictable safety and tolerability profile.

All press releases naming this drug 8 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Trifluridine/Tipiracil ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491159 ↗
Known as TAS-102 “Trifluridine/Tipiracil(TAS-102)” NCT07491159 ↗